WO2023154821A3 - Compositions comprising influenza hemagglutinin stem and method for enhancing cross-protective immunity - Google Patents

Compositions comprising influenza hemagglutinin stem and method for enhancing cross-protective immunity Download PDF

Info

Publication number
WO2023154821A3
WO2023154821A3 PCT/US2023/062320 US2023062320W WO2023154821A3 WO 2023154821 A3 WO2023154821 A3 WO 2023154821A3 US 2023062320 W US2023062320 W US 2023062320W WO 2023154821 A3 WO2023154821 A3 WO 2023154821A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigens
influenza hemagglutinin
improved
compositions
stem
Prior art date
Application number
PCT/US2023/062320
Other languages
French (fr)
Other versions
WO2023154821A2 (en
Inventor
Jesse Erasmus
Original Assignee
University Of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Washington filed Critical University Of Washington
Publication of WO2023154821A2 publication Critical patent/WO2023154821A2/en
Publication of WO2023154821A3 publication Critical patent/WO2023154821A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Improved influenza hemagglutinin (HA) antigens that include a stem (HA2) domain and a transmembrane domain to tether the antigen to a cell membrane for improved immunogenicity with vaccination. In embodiments, the tethered, miniature HA antigens include amino acid residue substitutions, additions, and/or deletions for stabler trimerization at the cell membrane and do not include all or part of the HA2 head subdomain. In embodiments, the improved antigens facilitate production of cross-reactive antibodies against the stem domain. In embodiments, the antigens are encoded by RNA of an RNA vaccine and administered to individuals for broad immunogenicity against influenza viruses.
PCT/US2023/062320 2022-02-11 2023-02-09 Compositions comprising influenza hemagglutinin stem and method for enhancing cross-protective immunity WO2023154821A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263309282P 2022-02-11 2022-02-11
US63/309,282 2022-02-11

Publications (2)

Publication Number Publication Date
WO2023154821A2 WO2023154821A2 (en) 2023-08-17
WO2023154821A3 true WO2023154821A3 (en) 2023-09-21

Family

ID=87565122

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/062320 WO2023154821A2 (en) 2022-02-11 2023-02-09 Compositions comprising influenza hemagglutinin stem and method for enhancing cross-protective immunity

Country Status (1)

Country Link
WO (1) WO2023154821A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117205309B (en) * 2023-11-07 2024-02-02 今发制药(南京)有限公司 Influenza immunogen composition, preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180008696A1 (en) * 2015-01-23 2018-01-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
US10117925B2 (en) * 2014-07-10 2018-11-06 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10117925B2 (en) * 2014-07-10 2018-11-06 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
US20180008696A1 (en) * 2015-01-23 2018-01-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens

Also Published As

Publication number Publication date
WO2023154821A2 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
US11938221B2 (en) Multivalent nanoparticle-based vaccines
Mett et al. A plant‐produced influenza subunit vaccine protects ferrets against virus challenge
Hervé et al. A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2
ES2832733T3 (en) Methods of preparation and use of influenza virus hemagglutinin complexes
Hagenaars et al. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
MY180109A (en) Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
US10925957B2 (en) Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza
MX345150B (en) Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses.
US11427619B2 (en) Methods of optimizing nucleotide sequences encoding engineered influenza proteins
US10548965B2 (en) Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian H5N1 influenza
WO2023154821A3 (en) Compositions comprising influenza hemagglutinin stem and method for enhancing cross-protective immunity
CA2863981A1 (en) Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
WO2019246363A8 (en) Mosaic influenza virus hemagglutinin polypeptides and uses thereof
WO2008060385A3 (en) Li-key enhanced vaccine potency
AU2013352179A8 (en) Computationally optimized broadly reactive antigens for H1N1 influenza
JP5918870B2 (en) Improved vaccination against influenza
CN101899461B (en) Fusion gene capable of encoding influenza A virus NP protein and M2e polypeptide
TWI725253B (en) Recombinant virus, composition comprising the same, and uses thereof
Ross Universal Influenza Vaccine Approaches Using Full-Length or Head-Only Hemagglutinin Proteins
Ji et al. Intranasal immunization with influenza virus-like particles containing membrane-anchored Cholera Toxin B or Ricin Toxin B enhances adaptive immune responses and protection against an antigenically distinct virus
WO2024015982A3 (en) Modified hiv envelope antigens and method of use thereof
WO2022261297A3 (en) Broadly reactive viral antigens as immunogens, compositions and methods of use thereof
Bhatnagar Adjuvant Effects on Enhancing Influenza Vaccine Effectiveness and Heterologous Prime-Boost Influenza Vaccination Strategy
WO2021142256A3 (en) Broadly reactive viral antigens as immunogens, compositions and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23753670

Country of ref document: EP

Kind code of ref document: A2